CSIMarket


Lifecore Biomedical Inc   (LFCR)
Other Ticker:  
 

Lifecore Biomedical Inc

LFCR's Fundamental analysis








Looking into Lifecore Biomedical Inc growth rates, revenue grew in IV. Quarter 2023 from the same quarter a year ago. Ranking at No. 3422

Major Pharmaceutical Preparations industry recorded deterioration of revenues by -8.1 %



More on LFCR's Growth


Lifecore Biomedical Inc
realized net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 10.09 in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 1.33.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.37.


More on LFCR's Valuation
 
 Total Debt (Millions $) 85
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ -
 Net Income/Employee (TTM) $ -
 Receivable Turnover (TTM) 3.52
 Tangible Book Value (Per Share $) -0.74

Lifecore Biomedical Inc
realized net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 10.09 in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 1.33.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.37.


More on LFCR's Valuation

  Market Capitalization (Millions $) 176
  Shares Outstanding (Millions) 30
  Employees -
  Revenues (TTM) (Millions $) 133
  Net Income (TTM) (Millions $) -164
  Cash Flow (TTM) (Millions $) 17
  Capital Exp. (TTM) (Millions $) -
  Total Debt (Millions $) 85
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ -
  Net Income/Employee(TTM) $ -
  Receivable Turnover Ratio (TTM) 3.52
  Tangible Book Value (Per Share $) -0.74

  Market Capitalization (Millions $) 176
  Shares Outstanding (Millions) 30
  Employees -
  Revenues (TTM) (Millions $) 133
  Net Income (TTM) (Millions $) -164
  Cash Flow (TTM) (Millions $) 17
  Capital Exp. (TTM) (Millions $) -


    LFCR's Profitability Comparisons
Lifecore Biomedical Inc achieved increase in profitability, due to cost control. Operating Margin grew in IV. Quarter 2023 to 16.09 %.







  Ratio
   Capital Ratio (MRQ) 2.39
  Total Debt to Equity (MRQ) -
  Tangible Leverage Ratio (MRQ) -
  Asset Turnover Ratio (TTM) 0.5
  Inventory Turnover Ratio (TTM) 1.9



Lifecore Biomedical Inc achieved increase in profitability, due to cost control. Operating Margin grew in IV. Quarter 2023 to 16.09 %.



More on LFCR's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com